Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.71 |
| ▸ | RAB9A | P51151 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | FHIT | P49789 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.43 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4341080 | 0.88 | ALDH1A1 (0.73) | SMN1; SMN2RAB9AKMT2AGAAALDH1A1 | |
| SCHEMBL15422625 | 0.77 | KMT2A (1.00) | SMN1; SMN2RAB9AKMT2AGAAALDH1A1 | |
| SCHEMBL5717543 | 0.74 | GAA (0.69) | SMN1; SMN2RAB9AKMT2AGAAALDH1A1 | |
| SCHEMBL30022668 | 0.72 | ALDH1A1 (0.61) | SMN1; SMN2RAB9AKMT2AGAAALDH1A1 | |
| SCHEMBL29438150 | 0.72 | BRD9 (0.52) | SMN1; SMN2KMT2AGAAALDH1A1MAPT | |
| SCHEMBL18781445 | 0.71 | BRD9 (0.48) | SMN1; SMN2RAB9AGAAALDH1A1MAPT | |
| SCHEMBL2546655 | 0.70 | ALDH1A1 (0.69) | SMN1; SMN2RAB9AKMT2AGAAALDH1A1 | |
| SCHEMBL13578883 | 0.69 | KMT2A (0.55) | SMN1; SMN2RAB9AKMT2AGAAALDH1A1 | |
| SCHEMBL30716454 | 0.68 | RXFP1 (0.50) | GAAMAPTTHRBL3MBTL1CSNK2A2 | |
| SCHEMBL4326028 | 0.68 | MAPT (0.74) | SMN1; SMN2RAB9AKMT2AGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653088-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-02-18 | — | — | US | disclosed |
| US-8653088-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-02-18 | — | — | US | disclosed |
| US-8653088-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-02-18 | — | — | US | disclosed |
| US-20090325968-A1 | Compositions Useful as Inhibitors of Protein Kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090325968-A1 | Compositions Useful as Inhibitors of Protein Kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090325968-A1 | Compositions Useful as Inhibitors of Protein Kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-12-31 | — | — | US | disclosed |
| US-7601718-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601718-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-13 | — | — | US | disclosed |
| US-7601718-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-13 | — | — | US | disclosed |
| US-20040192682-A1 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192682-A1 | Compositions useful as inhibitors of protein kinases | GSK3A, GSK3B, CSNK1A1 | SMN1; SMN2 1310/4885RAB9A 2274/4885KMT2A 2215/4885 |
| US-20090325968-A1 | Compositions Useful as Inhibitors of Protein Kinases | GSK3A, GSK3B, GSKIP | SMN1; SMN2 1456/4885RAB9A 2024/4885KMT2A 1927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.